Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nautilus Biotechnology, Inc., a development stage life sciences company, engages in creating a platform technology for quantifying and unlocking the complexity of the proteome. It develops Nautilus Platform, a proteomics platform that includes end-to-end solution comprised of instruments, consumables, and software analysis. The company was founded in 2016 and is headquartered in Seattle, Washington.

Nautilus Biotechnology, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SEATTLE, JULY 28, 2026 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEOME ANALYSIS PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2026. SECOND QUARTER 2026 BUSINESS HIGHLIGHTS RECOGNIZED FIRST REVENUE IN THE SECOND QUARTER OF 2026, INCLUDING GRANT REVENUE FROM THE MICHAEL J.

NAUTILUS BIOTECHNOLOGY REPORTS SECOND QUARTER 2026 FINANCIAL RESULTS

SEATTLE, JULY 08, 2026 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT; OR NAUTILUS), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEIN ANALYSIS PLATFORM, TODAY ANNOUNCED IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER 2026 BEFORE MARKET OPEN ON TUESDAY, JULY 28, 2026. THE COMPANY'S MANAGEMENT WILL WEBCAST A CORRESPONDING CONFERENCE CALL BEGINNING AT 5:30 A.M.

NAUTILUS BIOTECHNOLOGY TO ANNOUNCE SECOND QUARTER 2026 FINANCIAL RESULTS ON JULY 28, 2026

SEATTLE, APRIL 28, 2026 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEOME ANALYSIS PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH31, 2026. FIRST QUARTER 2026 BUSINESS HIGHLIGHTS INITIATED OUR ITERATIVE MAPPING EARLY ACCESS PROGRAM, ENABLING BROADER ACCESS TO OUR VALIDATED TAU PROTEOFORM ASSAY, WITH BAYLOR COLLEGE OF MEDICINE AS OUR FIRST CUSTOMER IN A NATIONAL INSTITUTES OF HEALTH-FUNDED CANCER STUDY.

NAUTILUS BIOTECHNOLOGY REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS

 BAYLOR SELECTS THE NAUTILUS VOYAGER PLATFORM, NOW AVAILABLE THROUGH EARLY ACCESS PROGRAM, FOR DEVELOPMENT OF A FIRST-IN-CLASS COMPUTATIONAL MULTI-OMICS TOOLKIT  NIH-FUNDED PROJECT LEVERAGES COLLABORATORS' EXPERTISE IN SINGLE-MOLECULE PROTEOMICS AND PROTEIN ISOFORM QUANTIFICATION TO ADVANCE HIGH-RESOLUTION CANCER ISOFORM ANALYSIS

NAUTILUS BIOTECHNOLOGY ANNOUNCES BAYLOR COLLEGE OF MEDICINE AS FIRST EARLY ACCESS PROGRAM CUSTOMER FOR VOYAGER PLATFORM

SEATTLE, FEB. 19, 2026 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT; OR NAUTILUS), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEIN ANALYSIS PLATFORM, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE.

NAUTILUS BIOTECHNOLOGY TO PARTICIPATE IN THE TD COWEN 46TH ANNUAL HEALTH CARE CONFERENCE

 BUCK INSTITUTE'S DEPLOYMENT OF NAUTILUS' INSTRUMENT GENERATES TAU PROTEOFORM DATA, PROVIDING EXTERNAL VALIDATION OF THE COMPANY'S NEXT-GENERATION SINGLE-MOLECULE PROTEOMICS PLATFORM  JOINT RESEARCH RESULTS SHOW HIGH REPRODUCIBILITY ACROSS SITES AND INSIGHT INTO NOVEL TAU BIOLOGY, SIGNALING A FUNDAMENTAL SHIFT IN HOW PROTEOMICS TECHNOLOGY CAN ADVANCE HUMAN HEALTH AND LONGEVITY  DATA PRESENTATION AT THE 2025 HUPO WORLD CONGRESS SEMINAR REDEFINING PROTEOMICS WITH SINGLE-MOLECULE ITERATIVE MAPPING ON NOVEMBER 10

NAUTILUS BIOTECHNOLOGY REPORTS SUCCESSFUL INSTALLATION AND TESTING OF ITS FIRST FIELD EVALUATION UNIT AT THE BUCK INSTITUTE FOR RESEARCH ON AGING

SEATTLE, JULY 31, 2025 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT; OR NAUTILUS), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEOME ANALYSIS PLATFORM, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE30, 2025.

NAUTILUS BIOTECHNOLOGY REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS

SEATTLE, JULY 15, 2025 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT; OR NAUTILUS), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEIN ANALYSIS PLATFORM FOR QUANTIFYING THE PROTEOME, TODAY ANNOUNCED IT WILL REPORT FINANCIAL RESULTS FOR THE SECOND QUARTER 2025 BEFORE MARKET OPEN ON THURSDAY, JULY 31, 2025.

NAUTILUS BIOTECHNOLOGY TO ANNOUNCE SECOND QUARTER 2025FINANCIAL RESULTS ON JULY 31, 2025

DR. MALLICK TO BE INDUCTED INTO THE ACADEMY FOR RADIOLOGY AND BIOMEDICAL IMAGING RESEARCH'S ESTEEMED COUNCIL OF DISTINGUISHED INVESTIGATORS FOR HIS OUTSTANDING CONTRIBUTIONS TO MEDICAL IMAGING DR. MALLICK TO BE INDUCTED INTO THE ACADEMY FOR RADIOLOGY AND BIOMEDICAL IMAGING RESEARCH'S ESTEEMED COUNCIL OF DISTINGUISHED INVESTIGATORS FOR HIS OUTSTANDING CONTRIBUTIONS TO MEDICAL IMAGING

NAUTILUS BIOTECHNOLOGY CO-FOUNDER AND CHIEF SCIENTIST PARAG MALLICK, PH.D., HONORED WITH THE ACADEMY FOR RADIOLOGY AND BIOMEDICAL IMAGING RESEARCH'S DISTINGUISHED INVESTIGATOR AWARD

SEATTLE, OCT. 30, 2024 (GLOBE NEWSWIRE) -- NAUTILUS BIOTECHNOLOGY, INC. (NASDAQ: NAUT; OR NAUTILUS), A COMPANY PIONEERING A SINGLE-MOLECULE PROTEIN ANALYSIS PLATFORM, TODAY ANNOUNCED THE COMPANY WILL BE PARTICIPATING IN THE INAUGURAL GUGGENHEIM HEALTHCARE CONFERENCE.

Nautilus Biotechnology, Inc.

NAUT

Price

Financial Reports

No items found.

Press Releases

Nautilus Biotechnology, Inc.

NAUT.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NAUT